Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial

The Lancet Oncology

Volumn 15, Issue 11, 2014, Pages 1269-1278

  von Minckwitz, Gunter ^a   Puglisi, Fabio ^b   Cortes, Javier ^c   Vrdoljak, Eduard ^d   Marschner, Norbert ^e   Zielinski, Christoph ^f,g   Villanueva, Cristian ^h   Romieu, Gilles ⁱ   Lang, István ^j   Ciruelos, Eva ^k   De Laurentiis, Michele ^l   Veyret, Corinne ^m   de Ducla, Sabine ⁿ   Freudensprung, Ulrich ⁿ   Srock, Stefanie ⁿ   Gligorov, Joseph ^o  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

^c VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^d UNIVERSITY HOSPITAL SPLIT   (Croatia)

^e Outpatient Cancer Center   (Germany)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g Central European Cooperative Oncology Group Austria   (Austria)

^h UNIVERSITY HOSPITAL OF BESANÇON   (France)

ⁱ Institut du Cancer Montpellier   (France)

^j NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^k HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^l NATIONAL CANCER INSTITUTE   (Italy)

^m CENTRE HENRI BECQUEREL   (France)

ⁿ F HOFFMANN LA ROCHE LTD   (Switzerland)

^o SORBONNE UNIVERSITÉ   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERIBULIN; ESTROGEN RECEPTOR; GEMCITABINE; IXABEPILONE; LACTATE DEHYDROGENASE; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; MONOCLONAL ANTIBODY;

ABSCESS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; BONE METASTASIS; BREAST METASTASIS; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CEREBROVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FISTULA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HAND FOOT SYNDROME; HEART FAILURE; HUMAN; HYPERTENSION; HYPONATREMIA; INTENTION TO TREAT ANALYSIS; INTERACTIVE VOICE RESPONSE SYSTEM; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUDDEN CARDIAC DEATH; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; VENOUS THROMBOEMBOLISM; VISCERAL METASTASIS; VOMITING; WOUND HEALING IMPAIRMENT; AGED; BREAST NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; GENETICS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PATIENT SELECTION; PROCEDURES; PROTO ONCOGENE; REMISSION; RETREATMENT; SURVIVAL; TIME; TREATMENT OUTCOME; TUMOR INVASION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; GENES, ERBB-2; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; REMISSION INDUCTION; RETREATMENT; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84908126746     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70439-5     Document Type: Article

References (20)

1. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
2. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28:3239-3247.
3. Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative locally recurrent or metastatic breast cancer. J Clin Oncol 2011, 29:1252-1260.
4. Brufsky AM, Hurvitz S, Perez E, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011, 29:4286-4293.
5. Crawford Y, Ferrara N VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res 2009, 335:261-269.
6. Bagri A, Berry L, Gunter B, et al. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin Cancer Res 2010, 16:3887-3900.
7. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008, 26:5326-5334.
8. Grothey A, Flick ED, Cohn AL, et al. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiol Drug Saf 2014, 23:726-734.
9. Cartwright TH, Yim YM, Yu E, Chung H, Halm M, Forsyth M Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology. Clin Colorectal Cancer 2012, 11:238-246.
10. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013, 14:29-37. ML18147 Study Investigators.
11. Masi G, Loupakis F, Salvatore L, et al. A randomized phase III study evaluating the continuation of bevacizumab (BV) beyond progression in metastatic colorectal cancer (mCRC) patients (pts) who received BV as part of first-line treatment: results of the BEBYP trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol 2012, 23:ixe9. (LBA17).
12. Fleming TR, Rothmann MD, Lu HL Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 2009, 27:2874-2880.
13. Schemper M, Smith TL A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996, 17:343-346.
14. Baselga J, Segalla JG, Roché H, et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 2012, 30:1484-1491.
15. von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009, 27:1999-2006.
16. Smith I, Pierga JY, Biganzoli L, et al. Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. Breast Cancer Res Treat 2011, 130:133-143.
17. Aogi K, Masuda N, Ohno S, et al. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study. Breast Cancer Res Treat 2011, 129:829-838.
18. Ellis LM, Reardon DA Cancer: the nuances of therapy. Nature 2009, 458:290-292.
19. Gridelli C, Bennouna J, de Castro J, et al. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial. Clin Lung Cancer 2011, 12:407-411.
20. Brandes AA, Mason W, Pichler J, et al. Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?. Future Oncol 2014, 10:1137-1145.